UNICREDIT BANK/PUT/ELI LILLY & CO/600/0.1/18.12.24 Share Price

Warrant

DE000HC96HB7

Real-time BOERSE MUENCHEN 18:40:31 26/06/2024 BST
0.45 EUR -6.25% Intraday chart for UNICREDIT BANK/PUT/ELI LILLY & CO/600/0.1/18.12.24
Current month-48.39%
1 month-54.29%
Date Price Change
26/06/24 0.45 -6.25%
25/06/24 0.48 -2.04%
24/06/24 0.49 -7.55%
21/06/24 0.53 -1.85%
20/06/24 0.54 +5.88%

Real-time BOERSE MUENCHEN

Last update June 26, 2024 at 06:40 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer UniCredit UniCredit
WKN HC96HB
ISINDE000HC96HB7
Date issued 11/09/2023
Strike 600 $
Maturity 18/12/2024 (175 Days)
Parity 10 : 1
Emission price 6.68
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 10.35
Lowest since issue 0.27
Delta-0.04x
Omega 7.920
Premium34.1x
Gearing178.03x
Moneyness 0.6646
Difference Strike -300.7 $
Difference Strike %-50.12%
Spread 0.07
Spread %13.73%
Theoretical value 0.4750
Implied Volatility 39.67 %
Total Loss Probability 92.43 %
Intrinsic value 0.000000
Present value 0.4750
Break even 594.93 €
Theta-0.04x
Vega0.05x
Rho-0.02x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6 USD
Average target price
860.5 USD
Spread / Average Target
-4.87%
Consensus